Medicines from nature: are natural products still relevant to drug discovery?
Historically, most drugs have been derived from natural products, but there has been a shift away from their use with the increasing predominance of molecular approaches to drug discovery. Nevertheless, their structural diversity makes them a valuable source of novel lead compounds against newly dis...
Gespeichert in:
| Veröffentlicht in: | Trends in pharmacological sciences (Regular ed.) 1999-05, Vol.20 (5), p.196-198 |
|---|---|
| 1. Verfasser: | |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 198 |
|---|---|
| container_issue | 5 |
| container_start_page | 196 |
| container_title | Trends in pharmacological sciences (Regular ed.) |
| container_volume | 20 |
| creator | Harvey, Alan L. |
| description | Historically, most drugs have been derived from natural products, but there has been a shift away from their use with the increasing predominance of molecular approaches to drug discovery. Nevertheless, their structural diversity makes them a valuable source of novel lead compounds against newly discovered therapeutic targets. Technical advances in analytical techniques mean that the use of natural products is easier than before. However, there is a widening gap between natural-product researchers in countries rich in biodiversity and drug discovery scientists immersed in proteomics and high-throughput screening. |
| doi_str_mv | 10.1016/S0165-6147(99)01346-2 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_69801805</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0165614799013462</els_id><sourcerecordid>69801805</sourcerecordid><originalsourceid>FETCH-LOGICAL-c361t-1284590b5b09ba45994286a4ed5a1cb157079e17779c19e3ecd42c22e94be3753</originalsourceid><addsrcrecordid>eNqFkEtLAzEQgIMotlZ_gpKT6GE1z83GS5HiC1o8qOeQzU5lZR812S3035t2i3jzkhmYbzIzH0LnlNxQQtPbt_jIJKVCXWl9TSgXacIO0JhmiidccXmIxr_ICJ2E8EUI4ZzRYzSihEsRC2O0WEBRurKBgJe-rXFju97DHbYehtxWeOXbonddwKErqwp7qGBtmw53LS58_4mLMrh2DX4zPUVHS1sFONvHCfp4fHifPSfz16eX2f08cTylXUJZJqQmucyJzm1MtWBZagUU0lKXU6mI0kCVUtpRDRxcIZhjDLTIgSvJJ-hy-Deu9t1D6Ewdd4Cqsg20fTCpzgjNyBaUA-h8G4KHpVn5srZ-YygxW49m59FsJRmtzc6jYbHvYj-gz2so_nQN4iIwHQCIZ65L8Ca4EhoXbXpwnSna8p8RP1p1gc8</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>69801805</pqid></control><display><type>article</type><title>Medicines from nature: are natural products still relevant to drug discovery?</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Harvey, Alan L.</creator><creatorcontrib>Harvey, Alan L.</creatorcontrib><description>Historically, most drugs have been derived from natural products, but there has been a shift away from their use with the increasing predominance of molecular approaches to drug discovery. Nevertheless, their structural diversity makes them a valuable source of novel lead compounds against newly discovered therapeutic targets. Technical advances in analytical techniques mean that the use of natural products is easier than before. However, there is a widening gap between natural-product researchers in countries rich in biodiversity and drug discovery scientists immersed in proteomics and high-throughput screening.</description><identifier>ISSN: 0165-6147</identifier><identifier>EISSN: 1873-3735</identifier><identifier>DOI: 10.1016/S0165-6147(99)01346-2</identifier><identifier>PMID: 10354614</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Biological Products - pharmacology ; Chemistry, Pharmaceutical - methods ; Cloning, Molecular ; Combinatorial chemistry ; Convention on Biological Diversity ; Drug discovery ; Drug Evaluation, Preclinical ; Ecosystem ; High-throughput ; Humans ; Natural products ; Pharmaceutical industrial</subject><ispartof>Trends in pharmacological sciences (Regular ed.), 1999-05, Vol.20 (5), p.196-198</ispartof><rights>1999 Elsevier Science Ltd</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c361t-1284590b5b09ba45994286a4ed5a1cb157079e17779c19e3ecd42c22e94be3753</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0165614799013462$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10354614$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Harvey, Alan L.</creatorcontrib><title>Medicines from nature: are natural products still relevant to drug discovery?</title><title>Trends in pharmacological sciences (Regular ed.)</title><addtitle>Trends Pharmacol Sci</addtitle><description>Historically, most drugs have been derived from natural products, but there has been a shift away from their use with the increasing predominance of molecular approaches to drug discovery. Nevertheless, their structural diversity makes them a valuable source of novel lead compounds against newly discovered therapeutic targets. Technical advances in analytical techniques mean that the use of natural products is easier than before. However, there is a widening gap between natural-product researchers in countries rich in biodiversity and drug discovery scientists immersed in proteomics and high-throughput screening.</description><subject>Biological Products - pharmacology</subject><subject>Chemistry, Pharmaceutical - methods</subject><subject>Cloning, Molecular</subject><subject>Combinatorial chemistry</subject><subject>Convention on Biological Diversity</subject><subject>Drug discovery</subject><subject>Drug Evaluation, Preclinical</subject><subject>Ecosystem</subject><subject>High-throughput</subject><subject>Humans</subject><subject>Natural products</subject><subject>Pharmaceutical industrial</subject><issn>0165-6147</issn><issn>1873-3735</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1999</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkEtLAzEQgIMotlZ_gpKT6GE1z83GS5HiC1o8qOeQzU5lZR812S3035t2i3jzkhmYbzIzH0LnlNxQQtPbt_jIJKVCXWl9TSgXacIO0JhmiidccXmIxr_ICJ2E8EUI4ZzRYzSihEsRC2O0WEBRurKBgJe-rXFju97DHbYehtxWeOXbonddwKErqwp7qGBtmw53LS58_4mLMrh2DX4zPUVHS1sFONvHCfp4fHifPSfz16eX2f08cTylXUJZJqQmucyJzm1MtWBZagUU0lKXU6mI0kCVUtpRDRxcIZhjDLTIgSvJJ-hy-Deu9t1D6Ewdd4Cqsg20fTCpzgjNyBaUA-h8G4KHpVn5srZ-YygxW49m59FsJRmtzc6jYbHvYj-gz2so_nQN4iIwHQCIZ65L8Ca4EhoXbXpwnSna8p8RP1p1gc8</recordid><startdate>19990501</startdate><enddate>19990501</enddate><creator>Harvey, Alan L.</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19990501</creationdate><title>Medicines from nature: are natural products still relevant to drug discovery?</title><author>Harvey, Alan L.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c361t-1284590b5b09ba45994286a4ed5a1cb157079e17779c19e3ecd42c22e94be3753</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1999</creationdate><topic>Biological Products - pharmacology</topic><topic>Chemistry, Pharmaceutical - methods</topic><topic>Cloning, Molecular</topic><topic>Combinatorial chemistry</topic><topic>Convention on Biological Diversity</topic><topic>Drug discovery</topic><topic>Drug Evaluation, Preclinical</topic><topic>Ecosystem</topic><topic>High-throughput</topic><topic>Humans</topic><topic>Natural products</topic><topic>Pharmaceutical industrial</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Harvey, Alan L.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Trends in pharmacological sciences (Regular ed.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Harvey, Alan L.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Medicines from nature: are natural products still relevant to drug discovery?</atitle><jtitle>Trends in pharmacological sciences (Regular ed.)</jtitle><addtitle>Trends Pharmacol Sci</addtitle><date>1999-05-01</date><risdate>1999</risdate><volume>20</volume><issue>5</issue><spage>196</spage><epage>198</epage><pages>196-198</pages><issn>0165-6147</issn><eissn>1873-3735</eissn><abstract>Historically, most drugs have been derived from natural products, but there has been a shift away from their use with the increasing predominance of molecular approaches to drug discovery. Nevertheless, their structural diversity makes them a valuable source of novel lead compounds against newly discovered therapeutic targets. Technical advances in analytical techniques mean that the use of natural products is easier than before. However, there is a widening gap between natural-product researchers in countries rich in biodiversity and drug discovery scientists immersed in proteomics and high-throughput screening.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>10354614</pmid><doi>10.1016/S0165-6147(99)01346-2</doi><tpages>3</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0165-6147 |
| ispartof | Trends in pharmacological sciences (Regular ed.), 1999-05, Vol.20 (5), p.196-198 |
| issn | 0165-6147 1873-3735 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_69801805 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Biological Products - pharmacology Chemistry, Pharmaceutical - methods Cloning, Molecular Combinatorial chemistry Convention on Biological Diversity Drug discovery Drug Evaluation, Preclinical Ecosystem High-throughput Humans Natural products Pharmaceutical industrial |
| title | Medicines from nature: are natural products still relevant to drug discovery? |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-06T13%3A43%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Medicines%20from%20nature:%20are%20natural%20products%20still%20relevant%20to%20drug%20discovery?&rft.jtitle=Trends%20in%20pharmacological%20sciences%20(Regular%20ed.)&rft.au=Harvey,%20Alan%20L.&rft.date=1999-05-01&rft.volume=20&rft.issue=5&rft.spage=196&rft.epage=198&rft.pages=196-198&rft.issn=0165-6147&rft.eissn=1873-3735&rft_id=info:doi/10.1016/S0165-6147(99)01346-2&rft_dat=%3Cproquest_cross%3E69801805%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=69801805&rft_id=info:pmid/10354614&rft_els_id=S0165614799013462&rfr_iscdi=true |